Hexarelin Overview

Hexarelin functions as a multi-receptor peptide agonist influencing growth hormone release, metabolic signaling, and cardiovascular responses through GHS-R1a and CD36 receptor pathways. As a synthetic hexapeptide growth hormone secretagogue (GHS) that acts as a potent agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a, or ghrelin receptor), hexarelin demonstrates enhanced stability and potency compared to natural ghrelin. Research models examine hexarelin’s effects on GH pulsatility, IGF-1 production, cardiac function, and metabolic regulation in laboratory and preclinical experimental settings, with particular interest in its cardioprotective and metabolic actions.

Xu et al. (2014).

History

Hexarelin was developed in the 1990s as part of systematic research into growth hormone-releasing peptides (GHRPs), following the identification of GHRP-6 and other early GHS compounds. Synthesized to optimize GH-releasing potency and duration of action, hexarelin emerged as one of the most potent synthetic GHS compounds. Subsequent research revealed its unexpected cardioprotective effects independent of growth hormone, leading to expanded investigation of its cardiovascular applications.

Granata et al. (2014).

Hexarelin Structure

CAS#: 140703-51-1

Molecular Formula: C₄₇H₅₈N₁₂O₆

Molecular Weight: 887.04 g/mol

PubChem ID: 6918245

Research Findings

Hexarelin has been investigated in growth hormone secretagogue research and cardiovascular pharmacology studies, with particular focus on GHS-R1a receptor activation, cardiac protection mechanisms, metabolic effects, and multi-tissue signaling responses in experimental animal models and cellular assays.

Key Areas of Research:

• Endocrine regulation: GH secretion, IGF-1 production, pituitary receptor expression

• Cardiovascular function: Cardioprotection, ischemia-reperfusion injury, cardiac remodeling

• Metabolic signaling: Lipid metabolism, insulin sensitivity, energy homeostasis

• Receptor pharmacology: GHS-R1a activation, CD36 binding, receptor tissue distribution

These findings demonstrate hexarelin’s versatility as a research compound across endocrine, cardiovascular, and metabolic systems. Through dual receptor engagement (GHS-R1a and CD36), hexarelin provides a unique experimental platform for studying growth hormone regulation, cardiac protection mechanisms, and integrated metabolic-cardiovascular signaling in diverse research models.

Huang et al., International Heart Journal, 2017

References

Xu X.B. et al. (2014). One dose of oral hexarelin protects chronic cardiac function after myocardial infarction. Peptides, 56:156-162.

Huang J. et al. (2017). The growth hormone secretagogue hexarelin protects rat cardiomyocytes from in vivo ischemia/reperfusion injury through interleukin-1 signaling pathway. International Heart Journal, 58(2):257-263.

Granata R. et al. (2014). The cardiovascular action of hexarelin. Journal of Geriatric Cardiology, 11(3):253-260.